Okazaki fragments, replication fork explain easy
"DNA Replication"[MeSH Terms] AND Okazaki
Okazaki fragments replication fork DNA replication explanation NIH
Helicase opens DNA
↓
Old DNA strand ========\
\ ← Replication fork
\
Old DNA strand ===========
Leading strand: ----------------------------> continuous
Lagging strand: <--- <--- <--- <--- short pieces
Okazaki fragments
↓
DNA ligase joins them
| Feature | Leading strand | Lagging strand |
|---|---|---|
| DNA synthesis | Continuous | Discontinuous |
| Made as | One long piece | Many Okazaki fragments |
| Needs primers | One main primer | Many primers |
| Final joining by ligase | Not much needed between pieces | Yes, joins fragments |
Transcription (prokaryotic & eukaryotic) + inhibitors
"RNA Polymerase"[MeSH Terms] AND transcription inhibitors
RNA transcription prokaryotes eukaryotes inhibitors alpha amanitin rifampin NIH
3′-TACG-5′5′-AUGC-3′TATAAT| Enzyme | Main product |
|---|---|
| RNA polymerase I | rRNA: 28S, 18S, 5.8S |
| RNA polymerase II | mRNA, miRNA, some snRNA |
| RNA polymerase III | tRNA, 5S rRNA, other small RNAs |
| Feature | Prokaryotes | Eukaryotes |
|---|---|---|
| Site | Cytoplasm | Nucleus |
| RNA polymerases | One | Three main nuclear polymerases |
| Promoter recognition | Sigma factor | General transcription factors |
| RNA processing | Minimal | Capping, splicing, poly-A tail |
| Transcription and translation | Coupled | Separate |
| mRNA type | Often polycistronic | Usually monocistronic |
| Inhibitor | Target / mechanism | Important point |
|---|---|---|
| Rifampicin (rifampin) | Binds bacterial RNA polymerase β subunit and blocks initiation/very early RNA-chain elongation | Used for tuberculosis; acts on prokaryotic RNA polymerase |
| Actinomycin D (dactinomycin) | Intercalates between DNA base pairs, blocking RNA polymerase movement | Inhibits transcription in both prokaryotic and eukaryotic cells; used as an anticancer drug |
| α-Amanitin | Toxin from Amanita mushrooms; inhibits eukaryotic RNA polymerases | Strongly inhibits RNA pol II, inhibits pol III at higher concentrations; pol I is resistant |
Post-transcriptional modifications
"RNA Processing"[MeSH Terms] AND eukaryotic
post transcriptional modifications mRNA 5 cap poly A splicing NCBI Bookshelf
Pre-mRNA
5′ ─ exon ─ intron ─ exon ─ intron ─ exon ─ 3′
↓ 5′ capping + splicing + 3′ polyadenylation
Mature mRNA
5′ cap ─ exon ─ exon ─ exon ─ poly-A tail
| Modification | What happens | Main function |
|---|---|---|
| 5′ capping | A 7-methylguanosine cap is added to the 5′ end | Protects mRNA, helps ribosome bind, assists nuclear export |
| 3′ polyadenylation | Many adenine nucleotides are added as a poly-A tail | Increases mRNA stability, export, and translation efficiency |
| Splicing | Introns are removed and exons are joined | Produces the correct coding sequence for protein synthesis |
5′ GU .......... AG 3′
Same gene → different exon combinations → different proteins
| Feature | Prokaryotic mRNA | Eukaryotic mRNA |
|---|---|---|
| 5′ cap | Usually absent | Present |
| Poly-A tail | Usually absent as a stabilizing tail | Present, stabilizes mRNA |
| Introns and splicing | Rare | Common |
| Location of processing | Minimal processing | Mainly nucleus |
| Translation | Can begin during transcription | Begins after processing and export |
Mutations, point mutation
"Point Mutation"[MeSH Terms]
point mutations missense nonsense silent frameshift NCBI Bookshelf
| Type | What changes? |
|---|---|
| Point mutation | One base pair is replaced by another |
| Insertion | One or more bases are added |
| Deletion | One or more bases are removed |
| Frameshift mutation | Insertion/deletion shifts the reading frame |
| Large-scale mutation | Large deletion, duplication, inversion, translocation, etc. |
Normal DNA: GAA
Mutated DNA: GTA
↑
one base changed
mRNA: GAA → glutamate
mRNA: GAG → glutamate
Normal mRNA: GAG → glutamate
Mutant mRNA: GUG → valine
Normal: UAU → tyrosine
Mutant: UAA → STOP
Normal: THE CAT ATE THE RAT
Deletion: THE ATA TET HER AT...
| Mutation | Protein effect |
|---|---|
| Silent | Same amino acid |
| Missense | One amino acid changed |
| Nonsense | Premature stop codon |
| Frameshift | Downstream amino acids altered |
| Splice-site | Abnormal mRNA processing |
Oncogenes & proto-oncogenes (activation mechanism
"Proto-Oncogenes"[MeSH Terms] AND activation
proto-oncogenes oncogenes mechanisms of activation gene amplification chromosomal translocation NCI
Normal proto-oncogene
↓ activating alteration
Oncogene
↓
Continuous / excessive growth signal
↓
Cancer development
RAS-GTP = ON
RAS-GDP = OFF
| Gene amplified | Important association |
|---|---|
| ERBB2 / HER2 | Breast and gastric cancers |
| N-MYC | Neuroblastoma |
| MDM2 | Some sarcomas |
| CCND1 (cyclin D1) | Some cancers, often also activated by translocation |
Normal: [MYC]
Amplified: [MYC] [MYC] [MYC] [MYC] [MYC]
↓
excess MYC protein
t(8;14)
MYC gene from chromosome 8
moves near
immunoglobulin heavy-chain enhancer on chromosome 14
↓
too much MYC expression
t(9;22) = Philadelphia chromosome
BCR gene + ABL gene
↓
BCR-ABL fusion protein
↓
constitutively active tyrosine kinase
↓
uncontrolled myeloid-cell proliferation
Viral promoter inserted near proto-oncogene
↓
excess gene transcription
↓
oncogene activation
Regulatory DNA mutation
↓
more transcription
↓
more normal growth-promoting protein
↓
excess proliferation
| Activation mechanism | Main result | Classic example |
|---|---|---|
| Point mutation | Hyperactive protein | RAS |
| Gene amplification | Excess normal protein | HER2, N-MYC |
| Translocation: enhancer/promoter swap | Overexpression of normal protein | MYC, t(8;14), Burkitt lymphoma |
| Translocation: fusion gene | New abnormal protein | BCR-ABL, t(9;22), CML |
| Viral insertion / regulatory change | Increased transcription | Retroviral activation |
| Feature | Proto-oncogene / oncogene | Tumor suppressor gene |
|---|---|---|
| Normal role | Promotes controlled growth | Restrains growth, repairs DNA, or triggers apoptosis |
| Cancer-causing change | Activation | Loss/inactivation |
| Type of mutation | Gain of function | Loss of function |
| Alleles usually needed | One | Usually both |
| Examples | RAS, MYC, HER2, BCR-ABL | TP53, RB, APC, BRCA1/2 |
Tumour suppressor genes (p53, Rb)
"Tumor Suppressor Protein p53"[MeSH Terms] AND retinoblastoma protein
p53 Rb tumor suppressor genes cell cycle p21 E2F NCI
Active Rb (hypophosphorylated)
↓ binds
E2F
↓
DNA-synthesis genes remain OFF
↓
Cell stays in G1 phase
Growth factors
↓
Cyclin D + CDK4/6
↓ phosphorylates
Rb becomes inactive
↓ releases
E2F
↓
S-phase genes ON
↓
G1 → S progression
Rb lost/inactive → E2F always free → DNA synthesis genes ON → uncontrolled division
DNA damage
↓
p53 becomes stabilized and activated
↓
p53 acts as a transcription factor
↓
p21 production increases
↓
p21 inhibits cyclin-CDK complexes
↓
Rb stays active and bound to E2F
↓
G1 → S arrest
Severe / unrepaired DNA damage
↓
p53
↙ ↘
senescence apoptosis
DNA damage
↓
p53 ↑
↓
p21 ↑
↓ inhibits CDKs
Rb remains hypophosphorylated and active
↓ binds
E2F
↓
No S-phase gene transcription
↓
Cell-cycle arrest
| HPV protein | Target | Result |
|---|---|---|
| E6 | p53 | Promotes p53 degradation, impaired apoptosis and DNA-damage response |
| E7 | Rb | Inactivates Rb, releases E2F, promotes S-phase entry |
| Feature | p53 | Rb |
|---|---|---|
| Gene | TP53 | RB1 |
| Nickname | Guardian of the genome | Governor of cell cycle |
| Core role | DNA-damage response, arrest, repair, apoptosis | Blocks G1 → S transition |
| Main downstream factor | p21 | E2F |
| Loss causes | DNA-damaged cells survive/divide | Uncontrolled DNA synthesis |
| HPV protein that inhibits it | E6 | E7 |
Molecular basis of cancer / chemical carcinogens
"Chemical Carcinogenesis"[MeSH Terms] AND mechanisms
chemical carcinogens initiation promotion direct acting indirect acting NCBI Bookshelf
| Gene group | Normal function | Cancer-causing change | Examples |
|---|---|---|---|
| Proto-oncogenes | Promote controlled growth | Gain-of-function activation | RAS, MYC, HER2, BCR-ABL |
| Tumor suppressor genes | Stop growth, repair damage, trigger apoptosis | Loss-of-function | TP53, RB, APC, BRCA1/2 |
| Apoptosis-regulating genes | Eliminate damaged cells | Reduced apoptosis | BCL2 overexpression, TP53 loss |
| DNA-repair genes | Correct DNA damage | Genomic instability | BRCA1/2, mismatch-repair genes |
| Telomerase-related pathways | Limit cellular lifespan | Telomerase reactivation allows limitless division | TERT activation |
Chemical exposure
↓
DNA adduct / DNA damage
↓
Mutation in oncogene or tumor-suppressor gene
↓
Abnormal cell survival and proliferation
↓
Cancer
Direct-acting chemical → directly reacts with DNA
Procarcinogen
↓ CYP450 metabolism
Ultimate carcinogen
↓
DNA damage / mutation
| Carcinogen | Common source | Important cancer association |
|---|---|---|
| Benzo[a]pyrene and other polycyclic aromatic hydrocarbons | Tobacco smoke, soot, coal tar, charred foods | Lung cancer and other smoking-related cancers |
| Aflatoxin B1 | Mold-contaminated peanuts/grains, Aspergillus flavus | Hepatocellular carcinoma, often linked with TP53 mutation |
| Aromatic amines and azo dyes | Dye, rubber, leather, chemical industries | Urothelial carcinoma of urinary bladder |
| β-naphthylamine | Industrial aromatic amine exposure | Bladder carcinoma |
| Vinyl chloride | PVC industry exposure | Hepatic angiosarcoma |
| Arsenic | Contaminated water, pesticides, industrial exposure | Skin cancer, lung cancer, angiosarcoma |
| Asbestos | Construction/insulation exposure | Mesothelioma and bronchogenic carcinoma |
| Nitrosamines / nitrosamides | Some preserved foods, tobacco-related exposure | Gastric and other gastrointestinal cancers |
| Alkylating agents | Chemotherapy | Therapy-related acute myeloid leukemia / myelodysplastic syndrome |
Initiator → DNA mutation → initiated cell
Initiated cell
+ repeated promoter exposure
↓
clonal expansion
↓
preneoplastic lesion
Initiation → Promotion → Progression → Malignant cancer
| Feature | Initiator | Promoter |
|---|---|---|
| Directly damages DNA? | Yes, usually | No, usually |
| Causes mutation? | Yes | No direct mutation |
| Effect reversible? | No | Often reversible early |
| Exposure required | Often single exposure can initiate | Repeated exposure usually needed |
| Main action | Produces initiated mutant cell | Expands the initiated clone |
PCR / RT-PCR
"Polymerase Chain Reaction"[MeSH Terms] AND "Reverse Transcriptase Polymerase Chain Reaction"
PCR RT-PCR reverse transcription PCR steps denaturation annealing extension NCBI Bookshelf
| Step | Temperature, approximate | What happens |
|---|---|---|
| Denaturation | 94-95°C | Double-stranded DNA separates into two single strands |
| Annealing | 50-65°C | Primers bind to complementary target sequences |
| Extension | 72°C | Taq polymerase extends primers and makes new DNA strands |
Double-stranded DNA
↓ heat
Two single DNA strands
↓ cooling
Primers attach
↓ Taq polymerase
New DNA copies made
1 DNA target → 2 → 4 → 8 → 16 → ...
RNA
↓ reverse transcriptase
cDNA
↓ PCR
Millions of DNA copies
| Feature | PCR | RT-PCR, reverse-transcription PCR |
|---|---|---|
| Starting material | DNA | RNA |
| Extra enzyme needed | No | Yes, reverse transcriptase |
| First product | Amplified DNA | cDNA, then amplified DNA |
| Main use | Detect DNA sequences | Detect RNA viruses or RNA expression |
RT-PCR: RNA → cDNA → endpoint PCR result
qPCR: DNA → PCR + fluorescence-based quantification
RT-qPCR: RNA → cDNA → real-time fluorescent PCR
Southern, Western, Northern blotting
Southern Northern Western blot differences DNA RNA protein NCBI Bookshelf